Gennex Laboratories Limited (BOM:531739)

Market Cap	2.47B -22.8%
Revenue (ttm)	1.52B +16.0%
Net Income	191.43M +1.6%
EPS	0.75 -1.4%
Shares Out	242.95M
PE Ratio	13.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	365,373
Average Volume	708,506
Open	10.37
Previous Close	10.21
Day's Range	9.52 - 10.49
52-Week Range	7.05 - 17.25
Beta	0.60
RSI	53.70
Earnings Date	May 29, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In fiscal year 2025, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.